Neurological complications of chemotherapy to the central nervous system

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 903-916

  Newton, Herbert B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855557782     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00031-8     Document Type: Chapter

References (85)

1. Adamson P.C., Balis F.M., McCully C.L., et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991, 9:670-674.
2. Adkins J.C., Peters D.H., Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997, 53:1005-1037.
3. Askoy M., Basu T., Brint J., et al. Thiamine status of patients treated with drug combinations containing 5-fluorouracil. Eur J Cancer 1980, 16:1041-1045.
4. Baker W.J., Royer G.L., Weiss R.B. Cytarabine and neurologic toxicity. J Clin Oncol 1991, 9:679-693.
5. Barry M., Clarke S., Mulcahy F., et al. Hydroxyurea-induced neurotoxicity in HIV disease. AIDS 1999, 13:1592-1594.
6. Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer 1996, 4:341-350.
7. Bleck T.P., Jacobsen J. Prolonged survival following the inadvertent intrathecal administration of vincristine: clinical and electrophysiologic analyses. Clin Neuropharmacol 1991, 14:457-462.
8. Bleyer W.A. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65:89-98.
9. Boileau G., Piro A.J., Lahiri S.R., et al. Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 1971, 55:595-598.
10. Brashear A., Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol 1997, 34:163-167.
11. Burns L.J. Ocular toxicities of chemotherapy. Semin Oncol 1992, 19:492-500.
12. Capri G., Munzone E., Tarenzi E., et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994, 86:1099-1101.
13. Cavaliere R., Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 2006, 6:218-226.
14. Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002, 29:963-965.
15. Chelbi-Alix M.K., Wietzerbin J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 2007, 89:713-718.
16. Chen J., Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005, 5:102-112.
17. Cheson B.D., Vena D.A., Foss F.M., et al. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994, 12:2216-2228.
18. Choi S.M., Lee S.H., Yang Y.S., et al. 5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci 2001, 16:328-334.
19. Chun H.G., Leyland-Jones B.R., Caryk S.M., et al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986, 70:1225-1228.
20. Clark A.W., Cohen S.R., Nissenblatt M.J., et al. Paraplegia following intrathecal chemotherapy: neuropathologic findings and elevation of myelin basic protein. Cancer 1982, 50:42-47.
21. D'Incalci M. Nitrosoureas: molecular pharmacology/translational research. Tumori 2007, 93:17-21.
22. Eggermont A.M., Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 2004, 40:1825-1836.
23. Eichler A.F., Batchelor T.T., Henson J.W. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-oncol 2007, 9:373-377.
24. Ettinger L.J. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982, 50:444-450.
25. Ettinger L.J., Freeman A.I., Creaven P.J. Intrathecal methotrexate overdose without neurotoxicity: case report and literature review. Cancer 1978, 41:1270-1273.
26. Formica V., Leary A., Cunningham D., et al. 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 2006, 58:276-278.
27. Garattini E., Gianni M., Terao M. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 2007, 13:1375-1400.
28. Gasco M., Argusti A., Bonanni B., et al. SERMs in chemoprevention of breast cancer. Eur J Cancer 2005, 41:1980-1989.
29. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998, 72:197-233.
30. Green M.R., Chowdhary S., Lombardi K.M., et al. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 2006, 6:635-652.
31. Halevy D., Radharkrishnan J., Markowitz G., et al. Thrombotic microangiopathies. Crit Care Clin 2002, 18:309-320.
32. Hammack J.E. Neurologic complications of chemotherapy and biologic therapies. Principles of Neuro-Oncology 2005, 679-709. McGraw-Hill Medical Publishing Division, New York. D. Schiff, B.P. O'Neill (Eds.).
33. Hurria A., Somlo G., Ahles T. Renaming "chemobrain" Cancer Invest 2007, 25:373-377.
34. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
35. Lajer H., Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999, 25:47-58.
36. Lee J.H., Kim S.W., Sung K.J. Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature. Clin Neurol Neurosurg 2000, 102:33-36.
37. Leveque D., Jehl F. Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol 2007, 47:579-588.
38. Maanen J.M., Smeets C.J., Beijnen J.H. Chemistry, pharmacology, and pharmacokinetics of N, N, N-triethylenethiophosphoramide (Thiotepa). Cancer Treat Rev 2000, 26:257-268.
39. Manetta A., Tewari K., Podczaski E.S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997, 66:20-26.
40. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003, 2:597-607.
41. Martincic D., Hande K.R. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif 2005, 22:101-121.
42. McKendrick J., Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005, 6:1231-1239.
43. McLean D.R., Clink H.M., Ernst P., et al. Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes. Cancer 1994, 73:3037-3040.
44. Melchert M., List A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39:1489-1499.
45. Mortensen M.E., Cecalupo A.J., Lo W.D., et al. Inadvertent intrathecal injection of doxorubicin with fatal outcome. Med Pediatr Oncol 1992, 20:249-253.
46. Nayfield S.G., Gorin M.B. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996, 14:1018-1026.
47. Neuwelt E.A., Glasberg M., Frenkel E., et al. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 1983, 14:316-324.
48. Newton H.B. Clinical pharmacology of brain tumor chemotherapy. Handbook of Brain Tumor Chemotherapy 2006, 21-43. Elsevier/Academic Press, Amsterdam. H.B. Newton (Ed.).
49. Newton H.B. Intra-arterial chemotherapy. Handbook of Brain Tumor Chemotherapy 2006, 247-261. Elsevier/Academic Press, Amsterdam. H.B. Newton (Ed.).
50. Newton H.B., Page M.A., Junck L., et al. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989, 7:39-45.
51. Newton H.B., Snyder M.A., Stevens C., et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas. J Neurooncol 2002, 56:79-86.
52. Newton H.B., Snyder M.A., Stevens C., et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of brain metastases. J Neurooncol 2003, 61:35-44.
53. Newton H.B., Dalton J., Figg G., et al. Longterm therapy of brain tumors with temozolomide: review of tolerability and efficacy in 47 patients (abstract). Neuro-oncol 2007, 9:522-523.
54. Nicolao P., Giometto B. Neurological toxicity of ifosfamide. Oncology 2003, 65:11-16.
55. Niemann B., Rpchlitz C., Herrmann R., et al. Toxic encephalopathy induced by capecitabine. Oncology 2004, 66:331-335.
56. Olin J.J. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park) 2001, 15:613-618.
57. Phillips K.A., Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 2003, 95:190-197.
58. Pirzada N.A., Ali I.I., Dafer R.M. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000, 34:35-38.
59. Pisoni R., Ruggenenti P., Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention, and management. Drug Saf 2001, 24:491-501.
60. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995, 6:7-13.
61. Postma T.J., Van Groeningen C.J., Witjes R.J., et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU, and vincristine (PCV) for recurrent glioma. J Neurooncol 1998, 38:69-75.
62. Price R.A., Jamieson P.A. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975, 35:306-318.
63. Raza S.M., Pradilla G., Legnani F.G., et al. Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther 2005, 5:477-494.
64. Renouf D., Gill S. Capecitabine-induced cerebellar toxicity. Clin Colorectal Cancer 2006, 6:70-71.
65. Robak T., Lech-Maranda E., Korycka A., et al. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13:3165-3189.
66. Rosenblum M.K., Delattre J.Y., Walker R.W., et al. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989, 7:269-281.
67. Rosenthal M.A., Ashley D.L., Cher L. Temozolomide-induced flare in high-grade glioma: a new clinical entity. Intern Med J 2002, 32:346-348.
68. Rowinsky E.K., Noe D.A., Grochow L.B., et al. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 1995, 13:1975-1984.
69. Russell M.T., Nassif A.S., Cacayorin E.D., et al. Gemcitabine-associated posterior leukoencephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 2001, 19:129-132.
70. Salloum E., Khan K.K., Cooper D.L. Chlorambucil-induced seizures. Cancer 1997, 79:1009-1013.
71. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003, 8:201-216.
72. Schold S.C., Fay J.W. Central nervous system toxicity from high-dose BCNU treatment of systemic cancer. Neurology 1980, 30:429.
73. Shingleton B.J., Bienfang D.C., Albert D.M., et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982, 100:1766-1772.
74. Sosman J.A., Sawhaney A. Cytokines and immunological monitoring. Cancer Chemother Biol Response Modif 1997, 17:217-286.
75. Spriggs D.R., Stopa E., Mayer R.J., et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer 1986, 46:5953-5958.
76. Takimoto C.H., Lu Z.H., Zhang R., et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996, 2:477-481.
77. Verma N., Kumar K., Kaur G., et al. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol 2007, 27:45-62.
78. Vezmar S., Becker A., Bode U., et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003, 49:92-104.
79. Videnovic A., Semenov I., Chua-Adajar R., et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005, 65:1792-1794.
80. Visani G., Manfroi S., Tosi P., et al. All-trans-retinoic acid and pseudotumor cerebri. Leuk Lymphoma 1996, 23:437-442.
81. Walker R.W., Cairncross J.G., Posner J.B. Cerebral herniation in patients receiving cisplatin. J Neurooncol 1988, 6:61-65.
82. Winick N.J., Bowman W.P., Kamen B.A., et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992, 84:252-256.
83. Wiseman L.R., Spencer C.M. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997, 10:473-485.
84. Yarbro J.W. Mechanism of action of hydroxyurea. Semin Oncol 1992, 19:1-10.
85. Yung W.K.A., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.